MA31367B1 - Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson. - Google Patents

Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson.

Info

Publication number
MA31367B1
MA31367B1 MA32333A MA32333A MA31367B1 MA 31367 B1 MA31367 B1 MA 31367B1 MA 32333 A MA32333 A MA 32333A MA 32333 A MA32333 A MA 32333A MA 31367 B1 MA31367 B1 MA 31367B1
Authority
MA
Morocco
Prior art keywords
pyridine
carboxamide
parkinson
dichloro
disease
Prior art date
Application number
MA32333A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Philippe Delay-Goyet
Claire Delgorge
Christine Menet
Gilles Poughon
Christine Ravinet-Trillou
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA31367B1 publication Critical patent/MA31367B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
MA32333A 2007-04-19 2009-11-10 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson. MA31367B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
PCT/FR2008/000534 WO2008145841A1 (fr) 2007-04-19 2008-04-16 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (1)

Publication Number Publication Date
MA31367B1 true MA31367B1 (fr) 2010-05-03

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32333A MA31367B1 (fr) 2007-04-19 2009-11-10 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson.

Country Status (33)

Country Link
US (1) US20100130554A1 (enExample)
EP (1) EP2146714B1 (enExample)
JP (1) JP5386478B2 (enExample)
KR (2) KR20150004885A (enExample)
CN (1) CN101663035B (enExample)
AR (1) AR066108A1 (enExample)
AT (1) ATE513548T1 (enExample)
AU (1) AU2008257322B2 (enExample)
BR (1) BRPI0810444A2 (enExample)
CA (1) CA2684174C (enExample)
CL (1) CL2008001136A1 (enExample)
CY (1) CY1111840T1 (enExample)
DK (1) DK2146714T3 (enExample)
EA (1) EA019194B1 (enExample)
ES (1) ES2367408T3 (enExample)
FR (1) FR2915100B1 (enExample)
HR (1) HRP20110666T1 (enExample)
IL (1) IL201448A (enExample)
JO (1) JO2678B1 (enExample)
MA (1) MA31367B1 (enExample)
ME (1) ME00935B (enExample)
MX (1) MX2009011284A (enExample)
MY (1) MY148092A (enExample)
NZ (1) NZ580482A (enExample)
PA (1) PA8776801A1 (enExample)
PL (1) PL2146714T3 (enExample)
PT (1) PT2146714E (enExample)
RS (1) RS51869B (enExample)
SI (1) SI2146714T1 (enExample)
TW (1) TWI439269B (enExample)
UY (1) UY31035A1 (enExample)
WO (1) WO2008145841A1 (enExample)
ZA (1) ZA200907251B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104955808A (zh) * 2012-11-28 2015-09-30 赛诺菲 4-(环丙基甲氧基)-n-(3,5-二氯-1-氧化吡啶-4-基)-5-甲氧基吡啶-2-甲酰胺的晶型的制备方法以及晶型
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
WO2025080415A1 (en) * 2023-10-12 2025-04-17 Alto Neuroscience, Inc. Treatment of neuropsychiatric disorders with tilivapram
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
ATE218549T1 (de) * 1993-07-28 2002-06-15 Aventis Pharma Ltd Verbindungen als pde iv und tnf inhibitoren
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
ATE290002T1 (de) * 1999-12-23 2005-03-15 Icos Corp Cyclische amp spezifische phosphodiesterase inhibitoren
EP1370211A4 (en) * 2001-03-02 2005-02-09 Bristol Myers Squibb Co SIMULTANEOUS ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONISTS AND A PHOSPHODIESTERASE HEMMER FOR THE TREATMENT OF DISEASES RELATED TO CYCLIC AMP
AU2003281219A1 (en) * 2002-07-02 2004-01-23 Bernard Cote Di-aryl-substituted-ethane pyridone pde4 inhibitors
AU2004220456B2 (en) * 2003-03-12 2010-10-14 Celgene Corporation N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
WO2006135828A2 (en) * 2005-06-10 2006-12-21 Memory Pharmaceuticals Corporation Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
CA2684174C (fr) 2014-02-25
FR2915100A1 (fr) 2008-10-24
PT2146714E (pt) 2011-09-02
JO2678B1 (en) 2013-03-03
CA2684174A1 (fr) 2008-12-04
ZA200907251B (en) 2011-04-28
ATE513548T1 (de) 2011-07-15
EP2146714B1 (fr) 2011-06-22
CN101663035B (zh) 2012-06-20
US20100130554A1 (en) 2010-05-27
HK1141725A1 (en) 2010-11-19
HRP20110666T1 (hr) 2011-10-31
KR20150004885A (ko) 2015-01-13
KR20090130059A (ko) 2009-12-17
UY31035A1 (es) 2008-11-28
BRPI0810444A2 (pt) 2016-05-31
CN101663035A (zh) 2010-03-03
DK2146714T3 (da) 2011-10-10
SI2146714T1 (sl) 2011-10-28
ES2367408T3 (es) 2011-11-03
EA200970970A1 (ru) 2010-02-26
JP5386478B2 (ja) 2014-01-15
CL2008001136A1 (es) 2009-01-16
FR2915100B1 (fr) 2009-06-05
MY148092A (en) 2013-02-28
CY1111840T1 (el) 2015-10-07
TWI439269B (zh) 2014-06-01
AR066108A1 (es) 2009-07-22
AU2008257322A1 (en) 2008-12-04
KR101503942B1 (ko) 2015-03-18
TW200911247A (en) 2009-03-16
IL201448A (en) 2014-08-31
WO2008145841A1 (fr) 2008-12-04
MX2009011284A (es) 2009-11-02
RS51869B (sr) 2012-02-29
EA019194B1 (ru) 2014-01-30
ME00935B (me) 2012-06-20
PA8776801A1 (es) 2008-11-19
AU2008257322B2 (en) 2013-06-13
PL2146714T3 (pl) 2011-10-31
IL201448A0 (en) 2010-05-31
EP2146714A1 (fr) 2010-01-27
NZ580482A (en) 2011-10-28
JP2010524906A (ja) 2010-07-22

Similar Documents

Publication Publication Date Title
MA30798B1 (fr) Thiazole pyrazolopyrimidines comme antigonistes du recepteur crf1
EP1838320A4 (en) CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL PROBLEMS
EP2063889A4 (en) SPIROPIPERIDINE BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA30632B1 (fr) Anticorps humanisé
MA33302B1 (fr) 2, 4-diaminopyrimidines pour le traitement de maladies caracterisees par une proliferation cellulaire excessive ou anormale
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
NO20084531L (no) Bruk av flibanserin for behandling av post-menopause seksuell lyst lidelser
FR2915398B1 (fr) "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
EP2683382A4 (en) DOSAGE SCHEMES FOR THE TREATMENT OF MORBUS FABRY
MA30514B1 (fr) Nouveaux composes.
EP2124988A4 (en) METHOD OF ACTIVATING OR BLOCKING THE HLA-E / QA-1 RESTRICTED CD8 + T-CELL REGULATORY PATH TO TREAT IMMUNE DISEASES
MA32506B1 (fr) Nouveaux composes
MA31798B1 (fr) Composés organiques
MA31198B1 (fr) Nouvelle forme dosifiee
MA31367B1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson.
DK1670903T3 (da) Behandling af neurodegenerative sygdomme
FR2891460B1 (fr) Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum.
DK1786442T3 (da) Behandling af neurodegenerative sygdomme under anvendelse af DEGS-inhibitorer
MA34489B1 (fr) Agonistes du récepteur a1 à l'adénosine destinés au traitement du glaucome et de l'hypertension oculaire
MA31369B1 (fr) Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere
EP2213290A4 (en) MEANS FOR IMPROVING MOTOR COMPLICATIONS OR PSYCHIATRIC SYMPTOMS AT MORBUS PARKINSON
MA33813B1 (fr) Utilisation d'une source de l3 et/ou de l5 comme vaccin ou comme diagnostic pour une maladie parasitaire
EP2219447A4 (en) S-ALKYLISOTHIOURONIUM DERIVATIVES FOR THE TREATMENT OF UTERUS HYPERCONTACTILITY DISORDERS
EP1889618A4 (en) Combined drug for treating diabetes